Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

893 results about "Cell immunity" patented technology

Cellular immunity, also known as cell-mediated immunity, is an important aspect of the immune system that allows the body to attack invading organisms on a cellular level.

Recombinant herpes zoster vaccine as well as preparation method and application thereof

ActiveCN119386170Ahigh titerstrong immune responseAntibody mimetics/scaffoldsViral antigen ingredientsHerpes zoster virusHerpes Zoster Vaccine
The invention discloses a recombinant herpes zoster vaccine as well as a preparation method and application thereof, and particularly relates to the technical field of biological medicines. The recombinant herpes zoster vaccine comprises a recombinant herpes zoster vaccine fusion protein purified product HN101 and a liposome mixture HA201, and the recombinant herpes zoster fusion protein gE-gD is constructed by recombining reconstructed gE protein and reconstructed gD protein. The gE-gD recombinant herpes zoster fusion protein is obtained by reconstructing gE protein of varicella-herpes zoster virus and gD protein of HSV through a gene recombination technology and then recombining the gE protein and the gD protein. After the gE-gD recombinant herpes zoster fusion protein is combined with a liposome mixture HA201, stronger immune response can be induced, the antibody titer and cellular immunity are improved, the vaccine effect is enhanced, and meanwhile, the potential infection risk is avoided.
Owner:JIANGSU WALVAX BIOTECHNOLOGY CO LTD

Varicella-zoster virus gE fusion protein as well as preparation method and application thereof

The invention belongs to the field of biological medicines, and particularly relates to a varicella-zoster virus gE fusion protein as well as a preparation method and application thereof. The varicella-zoster virus gE fusion protein comprises an amino acid sequence as shown in SEQ ID NO: 1 and at least one of the following fragments: a signal peptide, a Foldon sequence, a Ferritin sequence and a His tag sequence, the signal peptide can improve the protein expression quantity, the Foldon sequence can improve the stability of the protein, the particle size of an antigen can be increased, the immunogenicity of the antigen can be improved, and the fusion protein can be used for preparing a medicine for treating the varicella-zoster virus gE fusion protein. The Ferritin sequence can enhance immune response, a vaccine prepared from the gE fusion protein has excellent immunogenicity, and compared with a commercially available vaccine Shingrix, higher humoral immunity and cellular immunity levels can be induced.
Owner:BEIJING HUANUOTAI BIOMEDICAL TECH CO LTD

Antibody capable of binding to LILRB2 or antigen binding fragment thereof

The present invention provides antibodies, or antigen binding fragments thereof, capable of binding to leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2). The invention also provides application of the antibody or the antigen binding fragment thereof in preparation of drugs for treating diseases related to high expression of LILRB2. The antibody or the antigen binding fragment thereof provided by the invention can bind to human LILRB2 with high affinity, block the binding of the LILRB2 and the ligand HLA-G thereof, and enhance the T cell function.
Owner:KYINNO BIOTECHNOLOGY (BEIJING) CO LTD

High-pathogenicity porcine reproductive and respiratory syndrome virus mRNA vaccine composition and application thereof

The invention discloses a high-pathogenicity porcine reproductive and respiratory syndrome virus mRNA vaccine composition and application thereof. The vaccine composition is selected from any one of the following combinations: (1) an mRNA vaccine composition consisting of a PRRSV GP3 mRNA (messenger ribonucleic acid), a PRRSV GP4 mRNA (messenger ribonucleic acid) and a PRRSV GP5 mRNA (messenger ribonucleic acid); or (2) an mRNA vaccine composition consisting of a PRRSV GP5 mRNA, a PRRSV membrane protein (M) mRNA and a PRRSV nucleocapsid protein (N) mRNA. According to the invention, a high-pathogenicity PRRSV JX-A1 strain is used as a template, and mRNAs capable of synthesizing a plurality of fusion proteins GP345, GP5M and GP5MN and single structural proteins GP3, GP4, GP5, M and N are respectively constructed. After liposome encapsulation, mice are inoculated for immunological evaluation, and results show that humoral immunity and cellular immunity levels of a single mRNA-LNPs mixed group are higher than those of recombinant mRNA-LNPs, and GP5 + M + N and GP3 + 4 + 5 have relatively best effects. The invention provides a new technical means for preventing PRRSV (Porcine Reproductive and Respiratory Syndrome Virus).
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Construction method of pulmonary nodule benign and malignant differential diagnosis model based on single-cell immune spectrum

The invention provides a construction method of a pulmonary nodule benign and malignant differential diagnosis model based on a single cell immune spectrum. The method comprises the following steps: obtaining PBMC (peripheral blood mononuclear cells) by using a peripheral blood sample, and carrying out mass spectrum flow analysis on the PBMC to obtain a mass spectrum flow analysis data set; a PARC clustering algorithm is adopted, cells are divided into different phenotypes according to marker expression, the expression proportion of each cell subset is used as a modeling feature, a pulmonary nodule benign and malignant differential diagnosis model is obtained, and screening and early diagnosis of lung cancer are achieved. The technology has the characteristics of non-invasiveness, high sensitivity and high specificity, the diagnosis accuracy of lung cancer screening is improved, and an earlier treatment opportunity and a more suitable operation mode are provided for patients.
Owner:ZHEJIANG UNIV

Novel recombinant herpes zoster vaccine as well as preparation and application thereof

The invention belongs to the field of biomedicine, and particularly discloses a herpes zoster vaccine as well as a preparation method and application thereof. The invention provides a herpes zoster vaccine. A fusion protein in the herpes zoster vaccine comprises a VZV-gE protein, an Fc and an optional antigen epitope with a cellular immune activation effect. The adjuvant can be a combination of an MF59 adjuvant and a CpG1009 adjuvant, and enhances humoral immunity and cellular immunity at the same time. The vaccine formed by the fusion protein in cooperation with an innovative adjuvant system can induce generation of strong cellular immunity and humoral immunity.
Owner:CHENGDU NANOMICROGEN BIOTECH CO LTD +1

Lung adenocarcinoma prognosis risk prediction model and construction method and application thereof

The invention discloses a lung adenocarcinoma prognosis risk prediction model and a construction method and application thereof, and belongs to the technical field of biomedical detection. The lung adenocarcinoma (LUAD) prognosis model is successfully constructed by systematically analyzing the immune infiltration related gene (CAFRG) of tumor-associated fibroblasts (CAF), and the application value of the lung adenocarcinoma (LUAD) prognosis model in prediction of patient prognosis is verified. The CAFRG risk score is negatively related to the immune microenvironment score and is remarkably related to immune checkpoint gene expression, which suggests that a high-risk patient may have the characteristic of immune escape. Furthermore, based on TIDE tool analysis, the patients in the low-risk group have more active T cell immune response. The risk score is also closely related to the sensitivity of antitumor drugs, especially Doramapimod. Therefore, a new theoretical basis is provided for personalized treatment of lung adenocarcinoma, and a new direction is provided for future clinical research.
Owner:SUZHOU UNIV

Rabies virus G protein mutant as well as preparation method and application thereof

The invention relates to the technical field of biological medicines, in particular to a rabies virus G protein mutant as well as a preparation method and application thereof. The rabies virus G protein mutant is obtained by carrying out point mutation on an extracellular domain of G protein, the mutant realizes soluble expression of the extracellular domain of the G protein, can induce generation of a high-titer neutralizing antibody, and has more excellent cellular immunity and antibody immune response compared with commercial human rabies vaccines and canine rabies vaccines; the inoculation frequency is expected to be reduced, the immune procedure is shortened, and the immune dosage is reduced.
Owner:YANTAI PATRONUS BIOTECH CO LTD +1

Toxoplasma gondii attenuated vaccine strain RHdeltarop67 as well as construction method and application thereof

The invention discloses a toxoplasma gondii attenuated vaccine strain RH delta rop67 as well as a construction method and application thereof, and belongs to the technical field of parasitic disease prevention and control and biological product preparation. The attenuated vaccine strain is constructed by performing targeted knockout on the ROP67 gene in a toxoplasma gondii strain RH delta ku80 through a CRISPR / Cas9 mediated gene editing technology. Compared with a wild type strain, the attenuated vaccine strain shows remarkable attenuation characteristic and good immunogenicity. A test result shows that the attenuated vaccine strain can induce a host to generate specific immune response mainly based on cellular immunity, maintains a protection effect on toxoplasma gondii infection in a relatively long immune period, and has a protection effect on tachyzoite infection and a chronic infection stage of toxoplasma gondii strains with different virulence; the survival ability of a host to tachyzoite infection can be improved, and the formation level of cysts in tissues is reduced. The invention provides a technical scheme with long-term immune potential for research and development of toxoplasma gondii attenuated vaccines.
Owner:SHANXI AGRI UNIV

CAR-NK cell for knocking out KIR2DL5 targeting HER2, preparation method and application thereof

The invention provides a CAR-NK cell for knocking out KIR2DL5 targeting HER2 as well as a preparation method and application of the CAR-NK cell, and belongs to the technical field of genetic engineering.The CAR-NK cell is obtained by adopting a chimeric antigen receptor with HER2 as a target spot to infect an NK cell and then knocking out a KIR2DL5 gene; the chimeric antigen receptor taking the HER2 as the target spot comprises an HER2 single-chain antibody; the nucleic acid artificial sequence of the HER2 single-chain antibody is as shown in SEQ ID NO. 2. According to the application disclosed by the invention, the interaction of KIR2DL5-PVR is blocked by knocking out NK cell immune checkpoints, so that tumor immune escape is avoided, and the activity of killing tumor cells by CAR-NK cells is remarkably enhanced; according to the invention, by optimizing the nucleic acid artificial sequence of HER2, the secretion ability of CAR-NK cell factors, the tumor killing efficiency and the in-vivo inhibition effect on tumors can be improved.
Owner:SHANGHAI XINGRUIYIDA BIOTECHNOLOGY CO LTD

Monoclonal antibody targeting all subtypes of CD45 and application thereof

The invention discloses a monoclonal antibody targeting all CD45 subtypes and application of the monoclonal antibody, and belongs to the field of monoclonal antibody preparation. The hybridoma cell strain capable of stably secreting all anti-human CD45 subtype antibodies is successfully obtained by stably expressing short and long molecular subtypes of human CD45 extracellular regions in L929 mouse fibroblasts, immunizing BALB / c mice with L929 cells expressing the two molecular subtypes of human CD45, and fusing splenocytes with SP20 myeloma cells after the serum titer reaches the standard. And the monoclonal antibody targeting all subtypes of CD45 is obtained. The monoclonal antibody provided by the invention shows a high-affinity binding characteristic with all human CD45 molecular subtypes, has important application value in the aspect of human CD45 molecular detection, and can be used as a therapeutic antibody in the fields of tumor immunotherapy, autoimmune disease treatment, transplant rejection resistance and the like.
Owner:INST OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINESE ACADEMY OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE

ZIF-8 nano-particles loaded with mitoxantrone, preparation and application of ZIF-8 nano-particles in tumor chemical-immunotherapy

The invention relates to the technical field of medicines, and provides mitoxantrone-loaded ZIF-8 nanoparticles, a preparation method thereof and an application of the mitoxantrone-loaded ZIF-8 nanoparticles in tumor chemical-immunotherapy. Aiming at the defects of combined chemotherapy and immunotherapy clinically at the present stage, MIT ZIF-8 synthesized by a normal-temperature full-water-phase one-pot method is used as a novel chemical-immunotherapy scheme, and the capability of inducing cell immunogenic death of a chemotherapeutic drug mitoxantrone is enhanced by utilizing pyroptosis; the anti-tumor immune activation capability is enhanced while tumor cells are killed through chemotherapy, effective chemical-immune therapy is achieved, and the responsiveness of tumors to immune checkpoint inhibitor therapy is enhanced.
Owner:FUDAN UNIV SHANGHAI CANCER CENT

Inhibition of immune cells by immune checkpoint conjugates

The present invention provides cells (Immune Checkpoint Junction 'ICE' cells) having enhanced Immune Checkpoint Junction function. In some embodiments, the ICE cells have a PD-1 conjugation function (PD-1 conjugant cells). The ICE cells reduce adaptability and innate immunity when transplanted into a subject as compared to parental cells with corresponding unmodified immune checkpoint conjugation function. In some embodiments, the PD-1 zygote cells are low immune pluripotent (HIP) cells. In further embodiments, the HIP cell is type O blood (HIPO), rhesus monkey factor (Rh) negative (HIP-), or both type O and type Rh (HIPO-). In other embodiments, the PD-1 zygote cells have been derived or differentiated from HIP, HIP-, or HIPO-cells. In other embodiments, the ICE cell expresses a ligand that binds to a suppressive immune cell receptor selected from the group consisting of a LILRB1 zygote, a LILRB3 zygote, and a TIM3 zygote. In other embodiments, the ICE cell is a PD-1 zygote cell that also expresses a ligand that binds to another inhibitory immune cell receptor selected from the group consisting of CD47, truncated CD47, a LILRB1 zygote, a LILRB3 zygote, and a TIM3 zygote.
Owner:RGT UNIV OF CALIFORNIA

SaRNA vaccine for echinococcosis as well as preparation method and application of SaRNA vaccine

The invention discloses an SaRNA vaccine for echinococcosis as well as a preparation method and application of the SaRNA vaccine. The preparation method of the SaRNA vaccine comprises the following steps: carrying out codon optimization on a modified target antigen protein through a genetic engineering technology, then assembling the modified target antigen protein with a self-replicating protein sequence, 5 'UTR, 3' UTR and Poly (A) tail, carrying out gene synthesis, then cloning the synthesized gene into a plasmid, and carrying out purification to obtain the SaRNA vaccine. The preparation method comprises the following steps: constructing recombinant plasmids, sequentially carrying out plasmid linearization, in-vitro transcription and purification on the constructed recombinant plasmids to prepare SaRNA molecules, and finally wrapping the SaRNA molecules in lipid nanoparticles to form the SaRNA vaccine for the echinococcosis. Experiments prove that the SaRNA vaccine can activate humoral immunity and cellular immunity of mice at the same time, high-level EG95 specific antibodies and cytokines can be generated through low-dose immunity, and the SaRNA vaccine has wide application prospects in the aspect of preventing and / or treating the echinococcosis.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Severe fever with thrombocytopenia syndrome virus mRNA vaccine as well as preparation method and application thereof

The invention provides a chimeric bivalent SFTSV (severe fever with thrombocytopenia syndrome virus) mRNA (messenger ribonucleic acid) vaccine, which is characterized in that the vaccine co-expresses an SFTSV envelope protein precursor GPC and a nucleoprotein NP in series through a flexible joint. Through humoral immunity, cellular immunity and challenge protection effect evaluation, the effectiveness of the mRNA vaccine provided by the invention is verified. Research results show that the prepared SFTSV mRNA vaccine can generate a good immune protection effect by only needing one mRNA, has the characteristics of simple industrial production, easy quality control and the like, and is an ideal choice of the SFTSV vaccine.
Owner:UNIV OF SCI & TECH OF CHINA

Chicken infectious anemia virus-like particle as well as preparation method and application thereof

The invention discloses chicken infectious anemia virus-like particles as well as a preparation method and application thereof. The invention discloses a virus-like particle vaccine for preventing chicken infectious anemia. The virus-like particle vaccine comprises VP1 and VP2 proteins of chicken infectious anemia viruses. Chicken infectious anemia VP1 and VP2 proteins are expressed by using a baculovirus expression system, immunoblotting shows that the two proteins are successfully expressed in sf9 cells, electron microscope observation finds that the expressed proteins can be autonomously assembled into complete chicken infectious anemia virus-like particles, and the chicken infectious anemia virus-like particles have a space structure similar to that of an original virus and can be used for preparing chicken infectious anemia virus-like particles. Meanwhile, the virus-like particles have the advantages of high titer, high safety, capability of stimulating humoral immunity and cellular immunity and the like. The preparation method disclosed by the invention is simple, can be used for preparing the antigen protein of the chicken infectious anemia virus on a large scale, is high in expression quantity and short in time consumption, greatly reduces the production cost, and is suitable for large-scale production.
Owner:JIANGSU ACAD OF AGRI SCI

Aluminum-manganese composite nanocrystal, and preparation method therefor and use thereof

An aluminum-manganese composite nanocrystal, and a preparation method therefor and the use thereof. The method for preparing the aluminum-manganese composite nanocrystal comprises: step 1, mixing an aluminum salt solution, a manganese salt solution and an anionic adjuvant solution to obtain a mixture, and adjusting the pH value of the mixture to 5.5-8.5; and step 2, heating the mixture for a reaction, and washing the obtained solid reactant to obtain the aluminum-manganese composite nanocrystal. According to the aluminum-manganese composite nanocrystal prepared using the preparation method and the use thereof in the preparation of a vaccine adjuvant, a pharmaceutical composition, a drug delivery carrier or an immunogenic composition, the technical problem that an existing aluminum adjuvant cannot activate humoral immunity and cell immunity at the same time can be effectively solved.
Owner:THE GBA NAT INST FOR NANOTECHNOLOGY INNOVATION

Glycosylated ganoderic acid and anti-aging application thereof

The invention discloses glycosylated ganoderic acid with a chemical structural formula shown in the specification, the compound can effectively improve H2O2-induced cellular morphological change, remarkably reduce generation of reactive oxygen species (ROS) and reduce accumulation of beta-galactosidase in senescent cells, and in addition, cell immunoblotting analysis shows that the compound can be used for preparing glycosylated ganoderic acid. The glycosylated ganoderic acid can significantly down-regulate the expression of H2O2-induced senescence marker proteins p16 and p21, and experimental results prove that the glycosylated ganoderic acid has potential in the aspect of reversing cell senescence, provides a new candidate compound for the development of anti-senescence drugs, and shows a wide application prospect; # imgabs0 #
Owner:KUNMING UNIV OF SCI & TECH

Varicella-zoster virus mRNA vaccine and application thereof

The invention provides a varicella-zoster virus mRNA (messenger Ribonucleic Acid) vaccine and application thereof. The invention firstly provides an mRNA molecule, a coding region sequence of the mRNA molecule comprises a nucleotide sequence for coding an amino acid sequence as shown in SEQ ID NO: 1, and the coding region sequence preferably comprises a nucleotide sequence as shown in any one of SEQ ID NO: 2 to SEQ ID NO: 11, or a nucleotide sequence which has at least 93% similarity with the nucleotide sequence as shown in any one of SEQ ID NO: 2 to SEQ ID NO: 11 and codes the same amino acid sequence. When the mRNA molecule is used for preparing the vaccine, the production cost of the vaccine can be reduced, the physicochemical property of the vaccine is stable, the protein expression is improved to enhance the immune effect of the vaccine, and the humoral immunity and cellular immunity effects of the VZV-gE specificity are enhanced.
Owner:SHENZHEN RHEGEN BIOTECHNOLOGY CO LTD +1

Polypeptide for enhancing NK cell immune killing and inhibiting HSCs activation and application thereof

ActiveCN119101127AEnhance immune killing activityInhibitory activityPeptide/protein ingredientsDigestive systemPharmacy technologyPharmacy
The invention relates to the technical field of medicine and pharmacy, and discloses a polypeptide for enhancing NK cell immune killing and inhibiting HSCs activation and application of the polypeptide. The polypeptide obtained by the invention can cross vascular endothelium, can be used as a medium for connecting immune cells NK and hepatic fibrosis effector cells HSCs, and is beneficial to relieving hepatic fibrosis symptoms.
Owner:TIANJIN MEDICAL UNIV

Novel rabies virus nucleocapsid nanostructure vaccine and construction method thereof

The invention relates to a novel rabies virus nucleocapsid nanostructure vaccine and a construction method thereof, and belongs to the field of biomedicine.The nanostructure vaccine is characterized in that mRNA capable of efficiently expressing rabies virus G protein and recombinant rabies virus N protein expressed by escherichia coli are combined to form an NLS structure serving as a vaccine antigen component; and then wrapping with a lipid component. The vaccine constructed by the invention can form G antigen and N antigen integrated immunogen signal stimulation, so that specific immunity can form an effective reaction in humoral immunity and cellular immunity. In a protective test of challenge, the vaccine can achieve a 100% protection effect on mice.
Owner:WEIRUI BIOTECHNOLOGY (KUNMING) CO LTD +1

Classical swine fever virus subunit vaccine and preparation method thereof

The invention provides a classical swine fever virus subunit vaccine and a preparation method thereof, the classical swine fever virus subunit vaccine is based on an E2 protein gene and a GP67 signal peptide gene of a CSFV 1.1 strain, a recombinant expression vector is constructed through gene cloning, a classical swine fever virus E2 recombinant protein is obtained through expression of an insect baculovirus system, and the classical swine fever virus subunit vaccine is obtained. And the recombinant protein is combined with a colloidal manganese adjuvant to prepare the swine fever virus subunit vaccine. The hog cholera virus E2 recombinant protein is close to natural E2 protein in structural function, high in reduction degree, high in expression quantity and suitable for vaccine production and application; the vaccine can generate specific humoral immunity and relatively strong cellular immunity, and is beneficial to removal of CSFV in an animal body; meanwhile, the vaccine can be distinguished from attenuated vaccine strain immunization or wild strain infection at the nucleic acid level, can be used for preventing and purifying classical swine fever in an intensive pig farm, and has a considerable application prospect.
Owner:GIANTSTAR FARMING & ANIMAL HUSBANDRY CORP LTD

Novel influenza nanoparticle vaccine as well as preparation and application thereof

The invention belongs to the field of biomedicine, and particularly discloses a nasal spray influenza vaccine as well as a preparation method and application thereof. The invention provides a nasal spray influenza vaccine. Fusion protein in the nasal spray influenza vaccine comprises influenza virus strain HA protein or fragments thereof, influenza virus protein epitopes and ferritin. The adjuvant may be a CpG1009 adjuvant to enhance humoral and cellular immunity. A vaccine composed of the fusion protein and a novel CpG adjuvant can induce generation of a strong challenge protection effect.
Owner:CHENGDU NANOMICROGEN BIOTECH CO LTD +1

QS-21 saponin adjuvant as well as preparation method and application thereof

The invention relates to the technical field of biological pharmacy, and discloses a QS-21 saponin adjuvant as well as a preparation method and application thereof, the adjuvant is a composite liposome and comprises a liposome skeleton composed of distearoyl phosphatidylcholine and cholesterol, and QS-21 saponin, monophosphoryl lipid A and a local anesthetic are jointly entrapped in the liposome skeleton. The problem that high reactogenicity and immunogenicity of potent adjuvants are difficult to consider at the same time is solved, the immunostimulation component and the pain inhibition component are jointly entrapped in the same nano-carrier, collaborative delivery in injection local is achieved, and therefore pain and swelling caused by the adjuvants are accurately inhibited. The co-entrapment structure avoids the potential inhibition effect of the free anesthetic on the immune system, the potent body fluid and cellular immune enhancement activity of the adjuvant is completely reserved, and a new technical scheme is provided for developing vaccines with high safety and strong immune efficacy.
Owner:HUANUOTAI BIOMEDICAL TECHNOLOGY (CHENGDU) CO LTD

Capture probe, kit containing capture probe and application of capture probe in detection of T cell and B cell immune repertoire under spatial resolution

The invention belongs to the technical field of biological detection, and relates to a capture probe, a kit comprising the same and application of the capture probe in detection of T cell and B cell immune repertoire under spatial resolution. The capture probe comprises a transcript specific sequence; the transcript specific sequence is derived from the front 40 bp of a reverse complementary sequence of a J region transcript sequence, and the length of the transcript specific sequence is 20-35 bp. The advantages of using the capture probe to detect T cell and B cell immune repertoire under spatial resolution include that not all RNA with poly A tail is reversely transcribed, but only targeted RNA is reversely transcribed, so that the sequencing cost is remarkably reduced, and the detection is not limited by the poly A degradation degree of RNA in a sample.
Owner:HONGYI BIOTECHNOLOGY (CHENGDU) CO LTD

A method for preparing Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen

ActiveCN118931931BBacterial antigen ingredientsAntibacterial agentsClostridium perfringens epsilon toxinClostridial toxin
The invention discloses a method for preparing a Clostridium perfringens epsilon toxin-ferritin nanoparticle antigen, comprising constructing a soluble E toxin mutant and a soluble Ferritin protein respectively and purifying them, and then self-assembling the soluble E toxin mutant and the soluble Ferritin protein to form a nanoparticle antigen. The epsilon-ferritin nanoparticles prepared by the invention significantly promote the production of IgG in antigen-immunized mice and successfully induce a cellular immune response.
Owner:INSTITUTE OF ANIMAL SCIENCES OF CHINESE ACADEMY OF AGRICULTURAL SCIENCES

Varicella-zoster vaccine composition and use thereof

PCT designated stage expiredWO2025113554A1Viral antigen ingredientsAntiviralsAdjuvantNucleotide
A varicella-zoster vaccine composition and use thereof, belonging to the technical field of biological vaccines. The composition comprises a VZV gE antigen and a CpG ODN adjuvant and further comprises an aluminum adjuvant. The nucleotide sequence of the CpG ODN adjuvant is set forth in SEQ ID NO: 1. The CpG ODN adjuvant with a specific nucleotide sequence has better immunostimulatory activity. The provided varicella-zoster vaccine composition can generate a higher humoral immune response earlier and induce protective immunity in advance for at least one month. One immunization can reach or be close to the antibody level of two immunizations of the Shingrix vaccine. Moreover, the longer-time stable high-humoral immunity level can be kept, and cellular immunity can also be generated.
Owner:HUAPU SHIJIAZHUANG PHARMACEUTICAL CO LTD

Varicella zoster vaccine composition and application thereof

The invention discloses a varicella zoster vaccine composition and application thereof, and belongs to the technical field of biological vaccines, the composition comprises a VZV gE antigen, a CpG ODN adjuvant and an aluminum adjuvant, and the nucleotide sequence of the CpG ODN adjuvant is shown as SEQ ID NO: 1. According to the invention, the CpG ODN adjuvant with a specific nucleotide sequence is selected, so that the immunostimulatory activity is better; the varicella zoster vaccine composition provided by the invention can generate high humoral immune response earlier, and induces protective immunity for at least one month in advance; the antibody level of twice immunization of a Shigrix vaccine can be reached or close to once immunization, the stable high humoral immune level for a long time can be kept, and meanwhile cellular immunity can be generated.
Owner:HUAPU SHIJIAZHUANG PHARMACEUTICAL CO LTD

Pig group A rotavirus DNA vaccine and application thereof

The invention discloses a porcine group A rotavirus DNA vaccine and application thereof. The DNA vaccine is composed of an eukaryotic expression plasmid containing a G5 genotype VP7 protein gene sequence, an eukaryotic expression plasmid containing a G9 genotype VP7 protein gene sequence, an eukaryotic expression plasmid containing a P [23] genotype VP4 protein gene sequence and a TNF alpha adjuvant, the G5 genotype VP7 protein gene sequence is shown as SEQ ID NO: 1, the G9 genotype VP7 protein gene sequence is shown as SEQ ID NO: 2, and the P [23] genotype VP4 protein gene sequence is shown as SEQ ID NO: 3. The sequence of the P [23] genotype VP4 protein gene is as shown in SEQ ID NO: 3, and the sequence of the TNF alpha gene is as shown in SEQ ID NO: 4. The DNA vaccine prepared by the invention can cause remarkable humoral immunity and cellular immunity, and has a wide application prospect.
Owner:SANYA INSTITUTE OF NANJING AGRICULTURAL UNIVERSITY +1